Active ingredients: ivacaftor
What it is used for
KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have a G551D or other gating (class III) mutation or an R117H mutation in the CFTR gene
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Store in Original Container
- Lifetime is 36 Months.
Always read the label. If symptoms persist see your healthcare professional.
Light blue, film-coated tablet (16.5mm x 8.4mm in modified caplet shape). Each tablet is printed with "V 150" in black ink on one side only.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
Is this medicine subsidised?
This medicine is subsidised which may make it cheaper. To learn more about this subsidy, visit the Phamaceutical Benefits Scheme (PBS) website
Pregnant or planning a pregnancy?
For the active ingredient ivacaftor
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)
Kalydeco Tablets - myDr.com.au
Kalydeco Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Ivacaftor (marketed as Kalydeco), a new specific therapy for cystic fibrosis | Cochrane
What is the effect of ivacaftor on clinical outcomes (survival, quality of life and lung function) in people with cystic fibrosis?
Read more on Cochrane (Australasian Centre) website